A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.
Positive phase II data delight investors, but Madrigal Pharmaceuticals leads in the race to market.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.
Redhill Biopharma has claimed success with its novel Crohn's disease therapy, but there is more to this "victory" than meets the eye.
TG and Redhill are expecting phase III data soon, but both have a fight ahead to make their mark even if their projects succeed.
It's a start, but sham-controlled trials are needed.